AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05452187 — intervention group
Intervention type: OTHER
Intervention: Assessment of the impact of DAAs on the course of IBD.
Description: Qualitative variables will be expressed as a percentage and 95% confidence interval and quantitative variables as median and interquartile range. A priori it is difficult to determine which statistical analysis should be performed. It is basically a descriptive study, and the subsequent statistical analysis will depend on the evolution that the patients have presented in relation to the DAA treatment. If the drugs have been well tolerated without adverse effects, further statistical analysis will not be necessary. Instead, if the DAAs trigger activity outbreaks, variables related to the appearance of these outbreaks will be evaluated (type of DAA, immunomodulator, ...). To compare whether there are differences between the established groups, Chi Square (in qualitative independent variables), a t-student or ANOVA or their corresponding non-parametric tests (in quantitative independent variables) will be used. Statistical significance has been set at a probability level of \<0.05.
Study NCT05044715 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Treatment as usual-TAU groups include:~1. Mood Groups - General Process Groups~2. Anxiety Groups - Cognitive Behavioral Therapy~3. Body Image and Eating Concerns Groups~4. Reconciling Faith and Sexuality Groups
Study NCT05044715 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion-Focused Therapy (CFT)
Description: The CFT protocol assumes that participants have no prior experience with meditation, mindfulness, and self-compassion and teaches principles of each as well as skills such as guided meditations.
Study NCT05585983 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaxigrip Tetra Sanofi Pasteur Europe
Description: We will use 0.5 mL standard dose quadrivalent influenza vaccine containing 15 μg of hemagglutinin per strain consistent with WHO recommendations according to season.
Study NCT05585983 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vaxigrip Tetra Sanofi Pasteur Europe
Description: We will use 0.5 mL standard dose quadrivalent influenza vaccine containing 15 μg of hemagglutinin per strain consistent with WHO recommendations according to season.
Study NCT06319677 — intervention group
Intervention type: DEVICE
Intervention: ECMO treatment
Description: Critically ill patients were treated with ECMO while receiving antimicrobial therapy
Study NCT06220240 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified Training Programme
Description: Eccentric muscle contractions and 3-minute rest breaks will be used.
Study NCT06220240 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Training Programme
Description: A routine training program will be used.
Study NCT05111184 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education groupe
Description: Education
Study NCT04989595 — intervention group
Intervention type: DEVICE
Intervention: MyIUS app
Description: Data will be self-reported by participants through the MyIUS app.
Study NCT04799938 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 180 minutes of moderate-intensity exercise per week
Study NCT04837924 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fascia iliaca compartment block, (FICB) (levobupivacaine hydrochloride 0,25% 40 ml)
Description: Land mark technique will be used to perform FICB on the side of the hip fracture. The injection site is one centimetre caudal from the junction between medial 2/3 and lateral 1/3 in the imaginary line between anterior superior iliac spine and ipsilateral pubic tubercle. The goal is to administer local anesthetic in the fascia iliaca compartment.
Study NCT04837924 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: paracetamol 1 gram IV
Description: paracetamol 1 gram IV every six hours, 4 times in 24 hours
Study NCT04837924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol 1 gram IV
Description: paracetamol 1 gram IV every six hours, 4 times in 24 hours
Study NCT04837924 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Rescue analgesic tramadol 100 mg IV if needed
Description: Rescue analgesic, if needed, tramadol 100 mg in 100 ml saline (0,9% Sodium chloride) IV, up to 4 times in 24 hours
Study NCT04837924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue analgesic tramadol 100 mg IV if needed
Description: Rescue analgesic, if needed, tramadol 100 mg in 100 ml saline (0,9% Sodium chloride) IV, up to 4 times in 24 hours
Study NCT04837924 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Sting with blunt needle, (without piercing the skin), same site as fascia iliaca compartment block
Study NCT05742035 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venipuncture
Description: Bloodletting of 450 mL, followed by separation of the whole blood in 2 blood components: 1 red blood cell concentrate and 1 plasma. Measurement of the outcomes in the red blood cell concentrate.
Study NCT05742035 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Venipuncture
Description: Bloodletting of 450 mL, followed by separation of the whole blood in 2 blood components: 1 red blood cell concentrate and 1 plasma. Measurement of the outcomes in the red blood cell concentrate.
Study NCT05753878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HH-120 nasal spray, PartA cohort 1
Description: A single dose of HH-120 nasal spray premixed with 1mg/ml methylene blue injection.
Study NCT05753878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HH-120 nasal spray, Part A cohort 2-7
Description: A single dose of HH-120 nasal spray.
Study NCT05753878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HH-120 nasal spray, Part A cohort 8-9
Description: Two doses of HH-120 nasal spray.
Study NCT05753878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HH-120 nasal spray, Part B
Description: HH-120 nasal spray, 10 times daily for 7 consecutive days.
Study NCT05753878 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray, Part B
Description: Placebo nasal spray, 10 times daily for 7 consecutive days.
Study NCT06762314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Semaglutide is long acting glucagon like peptide which is parenterally administered as subcutaneous injection once weekly with a half-life of about 7 days
Study NCT06762314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: Empagliflozin lowers blood glucose levels by preventing glucose reabsorption in the kidneys, thereby increasing the amount of glucose excreted in the urine
Study NCT06761300 — intervention group
Intervention type: OTHER
Intervention: Psychological assessment
Description: Psychological assessment evaluation at different time points and its correlation with pain outcomes and satisfaction with the SCS intervention.
Study NCT05440006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fuzuloparib
Description: Fuzuloparib Capsules; 150mg; single dose per cycle.
Study NCT04810845 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of Class II A device SmartCardia
Description: Application of SmartCardia monitor patch 30 minutes before coronary angiography (2/3 devices per-patients would be applied). Non invasive recording of single-lead ECG, respiratory rate, pulse transit time, heart rate would occur pre, during and post (30 minutes) primary angioplasty procedure
Study NCT06398431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walking analysis sensor
Description: Participant gait analysis with the inertial sensor
Study NCT06184464 — intervention group
Intervention type: OTHER
Intervention: ACETATE LEUPRELINE
Description: USE ACETATE LEUPRELINE BEFORE AND AFTER PROSTATE DELIMITATION
Study NCT06279104 — intervention group
Intervention type: DRUG
Intervention: physician's choice of chemotherapy
Description: physician's choice of chemotherapy for relapsed/refractory ovarian clear cell carcinoma
Study NCT06279104 — intervention group
Intervention type: DRUG
Intervention: immune checkpoint inhibitor based therapy
Description: immune checkpoint inhibitor based therapy for relapsed/refractory ovarian clear cell carcinoma
Study NCT05686226 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E7 TCR-T cells
Description: Participants will receive a conditioning regimen consisting of cyclophosphamide and fludarabine. E7 TCR-T cells will be administered as a single intravenous infusion.
Study NCT05686226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Within 24 hours after E7 TCR-T cell infusion, aldesleukin 720,000 IU/kg IV every eight hours will be administered for up to six doses. Aldesleukin dosing will be stopped for aldesleukin-related grade 3 or greater toxicity other than flushing, fever, chills, or hemodynamic changes (tachycardia or hypotension) that respond to crystalloid infusion. Aldesleukin may also be stopped at any time at investigator discretion.
Study NCT06194955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GIP(1-42)
Description: Infusion
Study NCT06194955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GIP(1-42)
Description: Infusion
Study NCT06194955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GLP-1
Description: Infusion
Study NCT06194955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1
Description: Infusion
Study NCT06194955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-2
Description: Infusion
Study NCT06194955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GLP-2
Description: Infusion
Study NCT06194955 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT06194955 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT04410224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN004
Description: ASN004 is an antibody-drug conjugate for the treatment of advanced or metastatic solid tumors.
Study NCT05637294 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: splinting
Description: neutral-positioned wrist orthosis
Study NCT06488612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minced skin grafts for donor site
Description: After harvesting of STSG using watson's knife and coverage of the recipient site, the excess graft edges will be trimmed and together with any unused graft pieces will be collected in saline filled plate to prevent graft dissecation. Graft pieces will be placed over a rigid surface such as dorsum of a stainless steal jar or pot. Mincing of these small grafts will be done manually using large blade (no. 25) and sharp scissors. The resulting pasty graft mass composed of a large number of minced skin graft particles and a small amount of saline solution will be spread onto one half of the donor site using small dressing forceps.~Minced skin grafts will not be used on the other half (control side). The entire donor site will be covered with non-adherent absorbable dressing in the form of Vaseline gauze and sterilized cotton-filled dressing followed by elastic compression bandage.
Study NCT06420219 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study NCT04820257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home based exercise
Description: Exercise at home and behavioural change to increase daily exercise
Study NCT06453330 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Horizontal platelet-rich fibrin (H-PRF)
Description: Most commercially available centrifuges used for PRF production are fixed-angle systems designed primarily for pelleting samples to the bottom of tubes and are not particularly efficient at separating the cell layers effectively. Research has demonstrated that PRF produced using horizontal centrifugation (H-PRF) can lead to a higher concentration of platelets and leukocytes compared to PRF produced from fixed-angle centrifugation (LPRF). The resulting PRF from horizontal centrifugation is termed 'horizontal platelet-rich fibrin' (H-PRF). The H-PRF clot will be produced using a Bio-PRF horizontal centrifuge machine. This machine is CE marked and regularly used in the Dublin Dental University Hospital.
Study NCT05431452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain management
Description: Nonpharmacological pain management during blood collection in preterm infants
Study NCT05752201 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gamma Variant RBD-based ARVAC-CG vaccine
Description: Vaccine containing 50 µg of antigen + Alum. Schedule: One booster dose of vaccine Administration route: intramuscular (IM) injection
Study NCT05752201 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omicron Variant RBD-based ARVAC-CG vaccine
Description: Vaccine containing 50 µg of antigen + Alum. Schedule: One booster dose of vaccine Administration route: intramuscular (IM) injection
Study NCT05752201 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent RBD-based ARVAC-CG vaccine
Description: Vaccine containing 25 µg of gamma antigen + 25 µg of omicron antigen + Alum Schedule: One booster dose of vaccine Administration route: intramuscular (IM) injection
Study NCT05752201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (Alum)
Description: Schedule: One dose of placebo in a crossover design Administration route: intramuscular (IM) injection
Study NCT05641051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: Cases will receive 10 mg intravenous metoclopramide every 6 hours.
Study NCT05641051 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cases will receive the same volume of IV placebo / 6 hours.
Study NCT04882267 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Team and Technology
Description: Subjects will receive access and instruction on multiple home exercise apps. They will receive phone calls once a week from care team members for motivational interviewing to encourage exercise.
Study NCT04882267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team and Technology
Description: Subjects will receive access and instruction on multiple home exercise apps. They will receive phone calls once a week from care team members for motivational interviewing to encourage exercise.
Study NCT06241001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eccentric streching
Description: The player will lift up one leg from starting position so he stands on his to-be-trained leg. For performing eccentric exercises of the gastrocnemius muscles, the player will lower his heel until he will feel a slight stretch, while keeping his knee extended
Study NCT06241001 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IASTM
Description: Specially designed tools are used to apply longitudinal pressure along muscle fibers, and treatment usually includes applying to more than the tissues in the isolated location of the pain
Study NCT05496686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4.7 microCi 225Ac-MTI-201
Description: 4.7 microCi intravenous solution
Study NCT05496686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9.5 microCi of 225Ac-MTI-201
Description: 9.5 microCi intravenous solution
Study NCT05496686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 19 microCi of 225Ac-MTI-201
Description: 19 microCi intravenous solution
Study NCT05496686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 38 microCi of 225Ac-MTI-201
Description: 38 microCi intravenous solution
Study NCT05496686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 76 microCi of 225Ac-MTI-201
Description: 76 microCi intravenous solution
Study NCT05496686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 152 microCi of 225Ac-MTI-201
Description: 152 microCi intravenous solution
Study NCT05496686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 254 microCi of 225Ac-MTI-201
Description: 254 microCi intravenous solution
Study NCT05496686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 424 microCi of 225Ac-MTI-201
Description: 424 microCi intravenous solution
Study NCT05496686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 564 microCi of 225Ac-MTI-201
Description: 564 microCi intravenous solution
Study NCT05496686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 750 microCi of 225Ac-MTI-201
Description: 750 microCi intravenous solution
Study NCT05496686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 998 microCi of 225Ac-MTI-201
Description: 998 microCi intravenous solution
Study NCT05496686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1327 microCi of 225Ac-MTI-201
Description: 1327 microCi intravenous solution
Study NCT05826730 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric Exercises
Description: Eccentric Exercises for neck muscles.
Study NCT06237920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Induction with immune checkpoint blockade nivolumab on day 1. Nivolumab will also be administered on day 29. Response evaluation will be after the last cycle of checkpoint inhibition.
Study NCT06237920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Induction with immune checkpoint blockade nivolumab and relatlimab on day 1. Nivolumab and relatlimab will also be administered on day 29. Response evaluation will be after the last cycle of checkpoint inhibition.
Study NCT06333743 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser ablation
Description: Research has confirmed that laser ablation treatment of cervical HSIL is effective and feasible.
Study NCT06333743 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LEEP or Conization
Description: The most common treatment for HSIL is LEEP or conization of the cervical lesion, but there are several perinatal complications involved in this surgery.
Study NCT04719507 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae block
Description: ultrasound probe is placed parallel to the vertebral spine at T4 level and shifted 3 cm laterally to obtain the appropriate visualization. Under aseptic precautions, the needle is inserted and advanced perpendicular to the skin in all planes to contact the transverse process of the vertebra at a variable depth of 2-4 cm from the skin depending on the build of the individual. At this point, the needle tip lies between the erector spinae muscle and transverse process. After negative aspiration, 20 ml of 0.25% bupivacaine is administered in cephalad and caudal directions.
Study NCT04719507 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracic paravertebral block
Description: ultrasound probe is placed parallel to the vertebral spine at T4 level and shifted 2-3 cm laterally to obtain the appropriate visualization. Following the identification of pleura, transverse process and paravertebral space, the needle is inserted cranial to caudal direction using in-plane approach . After confirming the displacement of pleura with 0.5-1 ml of local anesthetic (LA), 20 ml of 0.25% bupivacaine is administered for the block.
Study NCT04719507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine Only Product in Parenteral Dose Form
Description: pethidine (1 mg/kg ) once
Study NCT05369455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae plane block
Description: determine the efficacy and safety of ultra-sound guided erector spine plane block for providing postoperative analgesia in pediatric patients scheduled for lower limb surgeries as regard pain score , duration of analgesia and total postoperative analgesic requirement as a primary outcome as well as their safety as regard hemodynamics, adverse events local complications as secondary outcomes.
Study NCT05369455 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided caudal block
Description: determine the efficacy and safety of ultra-sound guided caudal block for providing postoperative analgesia in pediatric patients scheduled for lower limb surgeries as regard pain score , duration of analgesia and total postoperative analgesic requirement as a primary outcome as well as their safety as regard hemodynamics, adverse events local complications as secondary outcomes.
Study NCT05639374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BASICS_HealthyClassroom
Description: First, they will complete a 22-item online questionnaire, collecting all the variables of the research. After completing it, the students in the intervention group will receive personalized feedback by mail that visually summarizes the content of the questionnaire. Students will receive a motivational intervention with the aim of increasing the university's awareness of their alcohol consumption. In the intervention session of the program, the following aspects may be addressed, whenever the participant wishes: 1) Pattern of alcohol consumption of the student; 2) Social norm of alcohol consumption; 3) Negative consequences of alcohol; 4) Costs of alcohol consumption; 5) The change; 6) Specific education on alcohol; and 7) Advice and recommendations.
Study NCT04830020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HMW-HA
Description: Aerolized administration b.i.d.
Study NCT04830020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HMW-HA
Description: Aerolized administration b.i.d.